27 Mar 2020
OFF-SITE AUDITS
Following the current COVID-19 pandemic, and in order to maintain the state of compliance and ensure fulfillment of GxP requirements, companies must now find alternatives to continue the qualification process of their sources.
26 Mar 2020
NITROSAMINES – RISK EVALUATION EXTENDED TO OCTOBER 2020
EMA has published an update on their website extending the completion date for the risk assessment of nitrosamines – step 1. The new submission deadline is the 1st of October 2020, more information is expected to be published tomorrow.
16 Mar 2020
COVID-19 - Business Continuity Plan Activation
Following recent developments and immediately after WHO announcement of COVID-19 virus outbreak classification as a pandemic, OWLPHARMA has decided to activate its business continuity plan.
21 Feb 2020
Safety Assessment of Cosmetic Products
Regulation (EC) no. 1223/2009 stipulates that all cosmetic products, prior to being marketed in the EU, must undergo a safety assessment carried out by a qualified person. The assessment must always be kept up to date, and any relevant information generated after the product is placed on the market has to be taken into account.
6 Feb 2020
Estamos a recrutar - Medical Writer
A OWLpharma tem em aberto uma vaga para Medical Writer no Departamento Médico-Científico, em Coimbra.